Comprehensive Snapshot for Actigraphy Device Market, Including Country and Segment Analysis in Brief.
Industry: Healthcare
Delivery Timelines: Please Contact Sales
Published Date: June-2025
Format: PPT*, PDF, EXCEL
Number of Pages: 197
ID: PMRREP35405
The global actigraphy device market size is predicted to reach US$ 11,488.2 Mn in 2032 from US$ 2,520.0 Mn in 2025. It will likely witness a CAGR of around 24.2% in the forecast period between 2025 and 2032.
Increasing prevalence of sleep disorders, lifestyle-related health issues, and chronic fatigue is propelling both researchers and clinicians to look beyond conventional diagnostic methods. Among the most promising solutions gaining traction is actigraphy, a technology that provides a non-invasive window into human rest-activity cycles. Compact, wearable, and smart actigraphy devices are now being used beyond sleep studies to monitor circadian rhythm disorders, mental health, and rehabilitation.
Key Industry Highlights
|
Global Market Attribute |
Key Insights |
|
Actigraphy Device Market Size (2025E) |
US$ 2,520.0 Mn |
|
Market Value Forecast (2032F) |
US$ 11,488.2 Mn |
|
Projected Growth (CAGR 2025 to 2032) |
24.2% |
|
Historical Market Growth (CAGR 2019 to 2024) |
16.2% |
Increasing emphasis on diagnosing and treating sleep disorders is envisioned to propel the actigraphy device market growth in the foreseeable future, states Persistence Market Research. These devices provide a non-invasive, cost-effective, and convenient method for monitoring sleep patterns over extended periods. The prevalence of sleep disorders such as restless legs syndrome, sleep apnea, and insomnia is surging across the globe, creating a high demand for these devices. According to the National Center for Health Statistics, around 14.5% of adults in the U.S. had trouble falling asleep every day or most days in 2020.
The number is projected to rise in the forecast period with changing lifestyles and underlying medical or psychiatric conditions. Several medical device companies have hence started innovating wearable technology. Modern devices now integrate artificial intelligence and machine learning algorithms to improve the accuracy of sleep monitoring. Companies such as Garmin, Apple, and Fitbit have already developed wearable devices that not only track sleep patterns but also monitor other health metrics, including oxygen saturation levels.
The demand for actigraphy tools in the sleep aid devices market is poised to hamper to a certain extent due to limitations in their ability to capture the full spectrum of sleep stages. Actigraphy primarily measures movement to infer sleep and wake states, lacking the ability to distinguish between different sleep stages such as non-REM and REM sleep. This issue arises as the devices do not record physiological signals, including muscle activity, eye movements, or brain activity, which are required for accurate sleep staging.
Actigraphy further tends to overestimate total sleep time and sleep efficiency while underestimating wakefulness, specifically in individuals with disturbed sleep patterns. This discrepancy is due to the device's reliance on movement. Hence, periods of immobility, even when awake, are often misclassified as sleep. Such inaccuracies are challenging in populations with fragmented sleep. It is evident among those with insomnia or sleep apnea where precise measurement of wakefulness is important.
Fitness and sports centers are increasingly integrating actigraphy devices to improve recovery monitoring, injury prevention, and athletic performance. These are further creating lucrative opportunities for actigraphy device manufacturers. Philips' Motion Biosensors exemplify this trend by offering trainers and athletes reliable feedback on sleep quality and energy use across multiple activities, including injury recovery, travel, and training. Such devices help enhance training and rehabilitation schedules by evaluating the ideal balance of sleep, activity, and rest required to maximize performance.
Wearable technology is also playing a significant role in recovery monitoring and injury prevention. By enabling real-time performance tracking, these devices enable athletes and coaches to access data on calories burned, heart rate, distance covered, and speed. These insights facilitate immediate adjustments to training programs, thereby improving performance and lowering the risk of overtraining. The ability of wearable sensors to analyze body movements to detect injury-prone patterns and support timely corrections is also projected to drive adoption.
Based on product, the market is bifurcated into wearable and handheld. Among these, the wearable segment will likely hold a share of approximately 58.4% in 2025, backed by their ability to provide continuous, non-invasive monitoring of sleep and activity patterns over extended periods. These enable users to collect data in natural, real-world environments, unlike conventional polysomnography that requires a clinical setting. Recent innovations in data analytics and sensor technology have improved the accuracy of these devices. Fitbit’s new models, for example, use multi-sensor data to enhance sleep stage estimation.
Handheld actigraphy devices, on the other hand, are predicted to witness decent growth through 2032 due to their increasing use in controlled clinical settings. Their portability and ease of use facilitate quick deployment in several healthcare environments, improving their appeal among healthcare professionals. Increasing emphasis on personalized healthcare is expected to drive demand for these devices as healthcare professionals require highly effective tools for treating sleep-related conditions. The incorporation of AI algorithms in these devices has also enabled sophisticated data analysis, delivering in-depth insights into sleep patterns.
In terms of application, the market is trifurcated into sleep disorders, physical activity monitoring, and chronic disease management. Out of these, sleep disorders are estimated to hold a share of about 29.6% in 2025, owing to the ability of actigraphy devices to non-invasively monitor sleep-wake patterns in naturalistic settings. The American Academy of Sleep Medicine (AASM) recommends the use of sleep tracking technologies, including actigraphy, in both adult and pediatric patients for assessing sleep disorders. These devices provide objective data that complements subjective sleep logs, offering a comprehensive view of a patient's sleep patterns.
Physical activity monitoring is predicted to witness a considerable CAGR from 2025 to 2032 as actigraphy devices are capable of providing valuable insights into daily activity patterns, which are important for managing various health conditions. In adolescents with chronic pain, these devices have been instrumental in quantifying reduced physical activity levels compared to their healthy peers. A study published in the Journal of Pediatric Psychology revealed that adolescents with chronic pain exhibited significantly lower activity levels, as measured by actigraphy. It points to the device’s role in assessing functional impairment in this population.
North America is anticipated to account for around 36.2% of the actigraphy device market share in 2025 due to a significant shift toward decentralized clinical trials and remote patient monitoring. Organizations such as the National Institutes of Health (NIH) and sleep research institutes are increasingly relying on actigraphy to collect longitudinal sleep data in non-clinical environments. Florida-based ActiGraph, for example, have witnessed a surge in partnerships with pharmaceutical companies, providing FDA-registered devices.
The U.S. actigraphy device market is expected to remain at the forefront of growth through 2032, backed by increasing inclination of sleep clinics and hospitals toward home-based, portable monitoring solutions. The Cleveland Clinic, for instance, has started using actigraphy as part of its digital health initiatives for managing circadian rhythm disorders and insomnia outside conventional lab settings. This points toward a key trend of reimbursable remote monitoring. It is supported by the Centers for Medicare & Medicaid Services (CMS) coding changes that encourage clinicians to use wearable sensors for chronic care management.
In Europe, the deployment of smart sleep tracking devices such as actigraphy in occupational health research is predicted to drive the market, especially in Germany and Scandinavia. A recent study funded by Sweden’s Karolinska Institute, for example, used actigraphy to examine sleep irregularities among shift workers in the transportation sector. It used CE-marked devices connected to cloud-based dashboards to analyze circadian misalignment. This further influenced labor policy discussions around night shifts and health.
The European Union’s Medical Device Regulation (MDR), which was fully implemented in 2021, has also resulted in a consolidation of vendors. Under this norm, only companies with CE-certified devices can participate in hospital tenders and public procurement. Hence, firms such as CamNtech in the U.K. and SOMNOmedics in Germany have strengthened their positions by updating their actigraphy devices to comply with these norms.
Japan is poised to experience high adoption rates of actigraphy devices in Asia Pacific due to increasing use by key companies to conduct in-depth studies on elderly health. This is reflected in research such as the Arakawa 85+ study, published in PubMed in 2020. It explored the relationship between physical activity and cognitive function in older adults. Using triaxial actigraphy, the study found that replacing sedentary time with light physical activity was associated with better cognitive function among elderly men.
China also represents one of the most prominent markets for sleep disorder therapeutics, where the government’s healthcare initiatives have bolstered interest in preventive diagnostics. Domestic giants such as Oppo and Huawei are incorporating actigraphy-style functionality into their smartwatches, with a few models capable of exporting raw movement data for research and clinical studies. In 2023, for example, Huawei launched the TruSleep 3.0 system designed to analyze sleep phases and micro-movements.
The actigraphy device market is highly competitive with the presence of several reputed medical device companies and emerging health tech start-ups. Leading players are emphasizing FDA-cleared, hospital-grade devices used in neurological research and sleep clinics. They are leveraging long-standing relationships with healthcare providers. Domestic brands, especially in Asia Pacific, are focusing on cost-effective solutions for surging sleep health awareness. They are targeting home health monitoring segments and primary care settings.
|
Report Attribute |
Details |
|
Historical Data/Actuals |
2019 - 2024 |
|
Forecast Period |
2025 - 2032 |
|
Market Analysis Units |
Value: US$ Bn/Mn, Volume: As Applicable |
|
Geographical Coverage |
|
|
Segmental Coverage |
|
|
Competitive Analysis |
|
|
Report Highlights |
|
|
Customization and Pricing |
Available upon request |
By Product
By Application
By End Use
By Region
To know more about delivery timeline for this report Contact Sales
The market is projected to reach US$ 2,520.0 Mn in 2025.
Surging prevalence of sleep disorders and increasing research studies on elderly care are the key market drivers.
The market is poised to witness a CAGR of 24.2% from 2025 to 2032.
Increasing demand for home healthcare services and rising investments in insomnia treatment options are the key market opportunities.
ActiGraph, LLC, ActivInsights Ltd., and Koninklijke Philips N.V. are a few key market players.
